Bayer is an innovation Life Science company with a more than 150-year history and core competencies in the fields of health care and agriculture. We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.
Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing mankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.
We are committed to operating sustainably and to addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation will enjoy excellent development opportunities at Bayer.
Focus on Life Science Businesses
Following the economic and legal separation of our MaterialScience business, now Covestro*, Bayer has charted the course for its successful development as a Life Science company. In this connection, we have realigned our corporate structure. Since January 1, 2016, Bayer’s core business has been managed by three divisions: Pharmaceuticals, Consumer Health and Crop Science. Animal Health is a separate reporting segment.
Dual governance system with the following governance bodies:
Business operations are the responsibility of the subgroups:
The Pharmaceuticals Division focuses on prescription drugs for the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. With its innovative pharmaceutical products, Bayer seeks to achieve a significant therapeutic benefit for patients while at the same time satisfying the growing requirements of physicians and health insurers. The Pharmaceuticals division in China is headquartered in Beijing with facilities in Beijing and Guangzhou. In anticipation of increasing product demand in China, Bayer invested EUR 100 million to significantly increase the production capacity of its Beijing plant. The capacity extension is designed to ensure a reliable supply of high-quality products to meet the Chinese market’s demand for pharmaceutical products, including the company’s cardiovascular and anti-diabetes products. The Pharmaceuticals Division’s Radiology business is a world-well-known diagnostic imaging solutions provider. In the field of Radiology, Bayer provides solution with imaging contrast media, injection devices and informatics in China.
Consumer Health Division
Bayer’s Consumer Health Division is a leader in the global consumer health marketplace. It operates in more than 100 countries and maintains several manufacturing and research-and-development (R&D) sites.
The division’s rich history of innovation began in 1899 with the introduction of Bayer’s well-known global consumer brand, Bayer Aspirin™. In 2005, Bayer acquired Roche’s OTC business and in October 2014 Bayer completed the acquisition of Merck’s global Consumer Care business. In November 2014, Bayer acquired 100 percent of the shares of the Chinese Dihon Pharmaceutical Group Co., Ltd.
Today, the Consumer Health division offers to consumers some of the world’s well-known and trusted medications and dietary supplements. The portfolio includes strong brands in various medical categories inwhich the company competes, including Allergy, Analgesics, Cardiovascular Risk Prevention, Cough & Cold, Dermatology, Foot Care, Gastrointestinals, Dietary Supplements and Sun Care.
Currently, the Consumer Health Division sells various influential brands on the Chinese market, including Talcid®, Elevit®, Kangwang®, Clarityne®, Eloson®, Pikangwang®, White & Black®, Canesten®, Redoxon®, Coppertone®, and others.
Crop Science Division
The Crop Science Division, a world-well-known crop protection solution provider, is committed to contributing to a sustainable development of agriculture by introducing innovation into the market. With a highly efficient and innovative portfolio, complete technical services and strong collaborations with local partners, the Crop Science Division China is aligned with the Chinese government’s efforts to modernize Chinese agriculture and dedicated to help farmers improve plant health, get better yields and gain more benefits.
Bayer has been active for over 60 years in Chinese agriculture, marked with constant efforts to introduce new technologies to Chinese farmers, ranging from Decis, an insecticide in early 1980s, to Luna Sensation launched in 2014, a fungicide for a wide range of vegetables and fruit. In March 2015, Crop Science launched 6 new innovative products in China covering crops of rice, corn, wheat, vegetables and fruits. In a total, over 20 new products are planned to be launched by 2020.
The Crop Science Division has also been carrying out projects in cooperation with authorities like the Ministry of Agriculture, the Chinese Academy of Agricultural Sciences as well as joint efforts with public partners on capacity building in agriculture. To support the latest government efforts in rural development, Bayer started collaboration with CITIC Trust in February 2014 on Innovation & Development of Modern Agricultural Technology on the background of Land Transfer. The collaboration aims to introduce financial services via the CITIC Trust, together with technology and innovation through Crop Science to Chinese agriculture, leveraging the rich experience and expertise of the two parties.
In the field of animal health, it offers a number of products for farm and companion animals. Bayer is a successful supplier of veterinary products in China with its head office and a GMP certified plant in Chengdu, Sichuan province.
The Bayer Group comprises around 302 consolidated companies** in 77 countries throughout the world. Global headquarters are in Leverkusen, Germany.
On December 31, 2017, the Bayer Group had 99,820 employees worldwide.